Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [9524]
News [23355]
Articles [1991]
Editorials [134]
Conferences [464]
elearning [298]
Recent advances in multiple myeloma therapy
Prof San Miguel, Prof Philippe Moreau, Prof Antonio Palumbo, Prof Meletios...
Recent advances in multiple myeloma therapy ( Prof San Miguel, Prof Philippe Moreau, Prof Antonio Palumbo, Prof Meletios Dimopoulos and Prof Thierry Facon )
14 Feb 2012
Recent advances in non-Hodgkin’s lymphoma therapy
Prof Mathias Rummel, Prof Umberto Vitolo, Prof Georg Hess, Prof Finbarr Cotter
Recent advances in non-Hodgkin’s lymphoma therapy ( Prof Mathias Rummel, Prof Umberto Vitolo, Prof Georg Hess, Prof Finbarr Cotter )
14 Feb 2012
The latest in prostate cancer imaging
Prof Anwar Padhani - Mount Vernon Cancer Institute, UK
The latest in prostate cancer imaging ( Prof Anwar Padhani - Mount Vernon Cancer Institute, UK )
3 Feb 2012
BTK inhibitor PCI-32765 induces durable responses in relapsed or refractory...
Prof Susan O’Brien - University of Texas MD Anderson Cancer Center, Houston
BTK inhibitor PCI-32765 induces durable responses in relapsed or refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma ( Prof Susan O’Brien - University of Texas MD Anderson Cancer Center, Houston )
9 Jan 2012
Obinutuzumab with rituximab in patients with relapsed CD20 and indolent B-Cell...
Dr Laurie Sehn - University of British Columbia, Vancouver, Canada
Obinutuzumab with rituximab in patients with relapsed CD20 and indolent B-Cell non-hodgkin lymphoma (GAUSS) ( Dr Laurie Sehn - University of British Columbia, Vancouver, Canada )
9 Jan 2012
ABVD chemo with radiation therapy for limited-stage hodgkin lymphoma
Dr Ralph Meyer - National Cancer Institute of Canada Clinical Trials Group
ABVD chemo with radiation therapy for limited-stage hodgkin lymphoma ( Dr Ralph Meyer - National Cancer Institute of Canada Clinical Trials Group )
9 Jan 2012
Two rituximab dosing strategies for low tumour burden follicular lymphoma...
Prof Brad Kahl - University of Wisconsin, Madison, USA
Two rituximab dosing strategies for low tumour burden follicular lymphoma (RESORT) ( Prof Brad Kahl - University of Wisconsin, Madison, USA )
9 Jan 2012
Cereblon expression required for anti-myeloma activity of lenalidomide and...
Prof Keith Stewart - Mayo Clinic, Scottsdale, USA
Cereblon expression required for anti-myeloma activity of lenalidomide and pomalidomide ( Prof Keith Stewart - Mayo Clinic, Scottsdale, USA )
9 Jan 2012
Tips and tricks in triple-negative breast cancer
Prof Martine Piccart - Jules Bordet Institute, Brussels, Belgium
Tips and tricks in triple-negative breast cancer ( Prof Martine Piccart - Jules Bordet Institute, Brussels, Belgium )
9 Jan 2012
Energy supply in cancer
Dr Michael Pollak - McGill Univeristy, Montreal, Canada
Energy supply in cancer ( Dr Michael Pollak - McGill Univeristy, Montreal, Canada )
20 Dec 2011
A new test to determine risk of recurrence in DCIS breast cancer
Dr Larry Solin - Albert Einstein Medical Center, Philadelphia, USA
A new test to determine risk of recurrence in DCIS breast cancer ( Dr Larry Solin - Albert Einstein Medical Center, Philadelphia, USA )
20 Dec 2011
A test to predict risk of recurrence in DCIS
Prof Joseph Sparano - Albert Einstein Cancer Center, New York, USA
A test to predict risk of recurrence in DCIS ( Prof Joseph Sparano - Albert Einstein Cancer Center, New York, USA )
20 Dec 2011

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation